Bank of New York Mellon Corp Has $23.37 Million Stake in Haleon PLC Sponsored ADR $HLN

Bank of New York Mellon Corp increased its stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 9.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,253,426 shares of the company’s stock after purchasing an additional 201,237 shares during the quarter. Bank of New York Mellon Corp owned about 0.05% of Haleon worth $23,368,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Hanson & Doremus Investment Management lifted its holdings in Haleon by 234.1% during the 2nd quarter. Hanson & Doremus Investment Management now owns 2,372 shares of the company’s stock worth $25,000 after buying an additional 1,662 shares in the last quarter. Banque Transatlantique SA acquired a new stake in shares of Haleon in the 1st quarter valued at $27,000. Ransom Advisory Ltd bought a new stake in shares of Haleon during the first quarter worth $31,000. Deutsche Bank AG lifted its stake in shares of Haleon by 267.8% during the first quarter. Deutsche Bank AG now owns 3,126 shares of the company’s stock valued at $32,000 after acquiring an additional 2,276 shares during the period. Finally, Hilltop National Bank acquired a new position in shares of Haleon during the second quarter valued at $33,000. Institutional investors and hedge funds own 6.67% of the company’s stock.

Wall Street Analyst Weigh In

HLN has been the subject of a number of research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a research report on Wednesday, October 8th. The Goldman Sachs Group raised shares of Haleon from a “neutral” rating to a “buy” rating in a research note on Wednesday, September 10th. Finally, Barclays downgraded shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $12.33.

Haleon Trading Down 3.3%

NYSE:HLN opened at $9.58 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.63 and a debt-to-equity ratio of 0.48. Haleon PLC Sponsored ADR has a 1-year low of $8.71 and a 1-year high of $11.42. The firm has a market capitalization of $42.64 billion, a price-to-earnings ratio of 24.55, a PEG ratio of 2.89 and a beta of 0.20. The business’s 50-day moving average price is $9.28 and its two-hundred day moving average price is $9.91.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.